Enzyme replacement therapy in lysosomal acid lipase deficiency — the intravenous infusion of recombinant human lysosomal acid lipase (LAL) to restore lipid metabolism in patients with Wolman disease and cholesteryl ester storage disease — represents the fastest-growing and only approved standard-of-care segment in the global acid lipase deficiency market, with the Acid Lipase...